Начало・Списък с акции・Lantheus Holdings Inc

Lantheus Holdings Inc

Затворен

СекторЗдравеопазване

101.01 0.52

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

99.64

Максимум

100.77

Ключови измерители
By Trading Economics
Приходи	75M 193M
Продажби	11M 388M
P/E Средно за сектора	24.141 57.371
EPS	1.32
Марж на печалбата	49.834
Служители	1,193
EBITDA	-69M 115M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+5.43% upside

Дивиденти
By Acuity
Следващи печалби	5.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.4M 6.6B
Предишно отваряне	100.49
Предишно затваряне	101.01

Настроения в новините

By Acuity

31%

69%

99 / 340 Класиране в Healthcare

Lantheus Holdings Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.08.2026 г., 19:36 ч. UTC

Lantheus Holdings Inc. shares are lower, impacted by a decline in the Health Care Supplies sub-sector. The asset remains near its one-month range low.

19.08.2026 г., 23:26 ч. UTC

Lantheus Holdings Inc. is seeing modest gains in after-market trading, with no specific news identified to explain the price movement.

13.08.2026 г., 20:06 ч. UTC

Lantheus Holdings Inc. is moving higher amid overall market gains, despite no specific company news to explain the advance.

12.08.2026 г., 23:36 ч. UTC

Lantheus Holdings Inc. shares declined in after-market trading, remaining below their 20-day moving average amid recent inflation data influencing investor sentiment.

3.08.2026 г., 19:56 ч. UTC

Social Media

News

Event

Lantheus Holdings Inc. to be acquired by Curium for up to $8 billion, offering $102.50 per share plus contingent value rights. Shares rise amid merger news.

31.07.2026 г., 22:01 ч. UTC

Lantheus Holdings Inc shares are lower in after-market hours amid weak trading conditions, remaining below the 20-day moving average and near a one-month low.

30.07.2026 г., 17:31 ч. UTC

Lantheus Holdings Inc is higher during Thursday's session, driven by overall market momentum, despite earlier downward pressure. The S&P 500 Index is also advancing.

29.07.2026 г., 21:42 ч. UTC

Lantheus Holdings Inc is trading lower in after-market hours, influenced by a decline in the broader market and rising oil prices amid geopolitical tensions.

28.07.2026 г., 19:42 ч. UTC

Social Media

Lantheus Holdings is in talks for a $7 billion acquisition by Curium, with shares declining despite the news and reaching a session low earlier.

27.07.2026 г., 22:51 ч. UTC

News

Lantheus Holdings is in talks for a $7 billion acquisition of Curium. Shares are trading lower in after-market hours amid deal evaluations.

24.07.2026 г., 22:01 ч. UTC

Lantheus Holdings Inc is trading lower in after-market hours, moving toward the lower end of its one-month trading range. No specific news was identified.

23.07.2026 г., 23:02 ч. UTC

Lantheus Holdings Inc. shares are lower in after-market trading, continuing a downward trend since Thursday's close, remaining below the 20-day moving average.

22.07.2026 г., 19:06 ч. UTC

Lantheus Holdings Inc shares are lower today, continuing a decline since Tuesday's close. Broader market sentiment is impacted by rising crude oil prices.

21.07.2026 г., 22:46 ч. UTC

Lantheus Holdings Inc shares are trading higher in after-market hours, supported by a broader market rebound, particularly in the tech sector.

20.07.2026 г., 19:46 ч. UTC

Lantheus Holdings Inc. shares are lower today, declining amid rising oil prices above $90 per barrel, contributing to inflationary pressures globally.

Сравнение с други в отрасъла

Ценова промяна

Lantheus Holdings Inc Прогноза

Ценова цел

By TipRanks

5.43% нагоре

12-месечна прогноза

Среден 105.4 USD 5.43%

Висок 115 USD

Нисък 102.5 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Lantheus Holdings Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Lantheus Holdings Inc през последните 3 месеца.

Настроение

By Acuity

99 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.